Drug

fluciclovine F-18

In clinical development

Emerging researchLate-stage developmentRising momentum

Also known as (18F)FACBC, (1R,3R)-1-amino-3(18F)fluorocyclobutane-1-carboxylic acid, 18F-Fluciclovine, Anti-1-amino-3-(18F)fluorocyclobutane-1-carboxylic acid+9 more

(18F)FACBC, (1R,3R)-1-amino-3(18F)fluorocyclobutane-1-carboxylic acid, 18F-Fluciclovine, Anti-1-amino-3-(18F)fluorocyclobutane-1-carboxylic acid, Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, FACBC, FACBC F-18, FLUCICLOVINE, Fluciclovine (18-F), Fluciclovine (18F), Fluciclovine F 18, Fluciclovine F18, Cyclobutanecarboxylic acid, 1-amino-3-fluoro-, trans-.

RxNorm1796118 ChEMBLCHEMBL254468UNII38R1Q0L1ZE

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)

Clinical trial2026-07-09Results expected Q4 2026 · ClinicalTrials.gov

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

Clinical trial2026-06-30Results expected Q4 2027 · ClinicalTrials.gov

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Clinical trial2026-06-25Results expected Q1 2029 · ClinicalTrials.gov

A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Clinical trial2026-06-24Results posted · ClinicalTrials.gov

Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

Clinical trial2026-06-18Results expected Q2 2027 · ClinicalTrials.gov

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Clinical trial2026-06-18Results expected Q4 2032 · ClinicalTrials.gov

The Impact of Fluciclovine (18F) PET on the Management of Participants With Prostate Cancer Following Negative or Equivocal PSMA PET Imaging at the Time of Biochemical Recurrence

Clinical trial2026-06-02Results expected Q4 2027 · ClinicalTrials.gov

Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)

Clinical trial2026-04-29Results expected Q4 2026 · ClinicalTrials.gov

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Clinical trial2025-12-01Results expected Q1 2030 · ClinicalTrials.gov

Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography-Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects.

Research2022-04-11International journal of radiation oncology, biology, physics

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.

Research2021-05-07Lancet (London, England)

Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients.

Research2018-02-24European journal of radiology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

fluciclovine F-18

Aliases & brands

(18F)FACBC(1R,3R)-1-amino-3(18F)fluorocyclobutane-1-carboxylic acid18F-FluciclovineAnti-1-amino-3-(18F)fluorocyclobutane-1-carboxylic acidAnti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acidFACBCFACBC F-18FLUCICLOVINEFluciclovine (18-F)Fluciclovine (18F)Fluciclovine F 18Fluciclovine F18Cyclobutanecarboxylic acid, 1-amino-3-fluoro-, trans-

RxNorm CUI

1796118

ChEMBL ID

CHEMBL254468

UNII

38R1Q0L1ZE